Market
What will be the adoption rate of prenatal blood tests for cancer detection in North America by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Reports or studies from healthcare institutions or research organizations
Story
NEJM Study: Prenatal Blood Test May Detect Hidden Cancers in 1 in 2 Pregnant Women
Dec 5, 2024, 11:45 AM
A study published in the New England Journal of Medicine (NEJM) has revealed that prenatal blood tests, specifically cell-free DNA (cfDNA) sequencing for fetal aneuploidy, can sometimes indicate the presence of hidden cancers in pregnant women. The IDENTIFY study found that among 107 participants with unusual or nonreportable results from these tests, approximately half were diagnosed with an occult cancer. Most of the genetic variants detected were copy number variations (CNVs) across multiple chromosomes. The study was conducted by commercial laboratories in North America and highlights the potential of prenatal testing to alert healthcare providers to maternal health issues beyond fetal conditions.
View original story
Similar markets
High adoption (75%+ countries) • 25%
Minimal adoption (<25% countries) • 25%
Low adoption (25-49% countries) • 25%
Moderate adoption (50-74% countries) • 25%
11-20% • 25%
31% or more • 25%
0-10% • 25%
21-30% • 25%
20% to 40% • 25%
Less than 20% • 25%
40% to 60% • 25%
More than 60% • 25%
1 to 5 countries • 25%
More than 10 countries • 25%
6 to 10 countries • 25%
No countries • 25%
Less than 20% • 25%
More than 60% • 25%
20% to 40% • 25%
40% to 60% • 25%
Not adopted • 25%
More than 50% of major hospitals • 25%
25% to 50% of major hospitals • 25%
Less than 25% of major hospitals • 25%
Germany • 25%
Other • 25%
USA • 25%
UK • 25%
More than 60% • 25%
Less than 20% • 25%
20-40% • 25%
40-60% • 25%
Breast Cancer • 25%
Gastrointestinal Cancer • 25%
Other • 25%
Lung Cancer • 25%